Research Analysts Offer Predictions for Ovid Therapeutics Inc.'s Q1 2024 Earnings (NASDAQ:OVID) : vimarsana.com

Ovid Therapeutics Inc. (NASDAQ:OVID – Free Report) – Equities research analysts at B. Riley issued their Q1 2024 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a research note issued to investors on Monday, April 29th. B. Riley analyst K. Patel expects that the company will earn ($0.26) per share for the […]

Related Keywords

China , United States , Jeremym Levin , , Ovid Therapeutics Company Profile , Ovid Therapeutics Inc , Securities Exchange Commission , Sg Americas Securities , China Universal Asset Management Co , Jump Financial , Connor Clark Lunn Investment Management Ltd , Nasdaq , Ovid Therapeutics , Free Report , Covid Therapeutic , Get Free Report , Universal Asset Management , Connor Clark , Lunn Investment Management , Exchange Commission , Therapeutics Inc , Ovid Therapeutics Daily , Nasdaq Ovid , Ovid , Medical , Earnings Estimates , B Riley ,